ERBB2 and breast cancer: Furthermore, a higher CCND1 amplification rate was also detected in TPBC compared with HR-negative, HER2-positive breast cancer, and more than 80% of TPBC were characterized by luminal A/B intrinsic subtype, indicating the sensitivity of TPBC to CDK4/6 inhibitor and endocrine therapy2.